ZIOPHARM Oncology, Inc. (ZIOP)(製薬・医療分野):企業M&A動向

◆英語タイトル:ZIOPHARM Oncology, Inc. (ZIOP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH24573D
◆発行会社(調査会社):GlobalData
◆発行日:2015年3月30日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary

ZIOPHARM Oncology, Inc. (ZIOPHARM Oncology) is a biopharmaceutical company. The company discovers and develops cancer therapies. Its products include palifosfamide, IL-12 DNA program, indibulin and darinaparsin. ZIOPHARM Oncology’s indibulin is a tubulin binding agent in phase II clinical trial in metastatic breast cancer; and darinaparsin is a novel organic arsenic molecule synthesized by conjugating dimethylarsenic to glutathione. Its activity includes disruption of mitochondrial function, inhibition of angiogenesis and modified signal transduction, leading to cell cycle arrest and apoptosis. Darinaparsin is active against hematological and solid cancers both in vitro and in vivo. The company partners with Intrexon Corporation. The company was formerly known as EasyWeb, Inc. ZIOPHARM Oncology is headquartered in Boston, Massachusetts, the US.

ZIOPHARM Oncology, Inc. (ZIOP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Ziopharm Expands Co-Development Agreement with Intrexon 10
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 11
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 13
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 14
Licensing Agreements 16
Intrexon, Ziopharm Oncology Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 16
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 18
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 20
Equity Offering 22
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 22
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 24
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 25
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 27
ZIOPHARM Oncology Completes Underwritten Public Offering For US$35 Million 29
ZIOPHARM Oncology Completes Public Offering For US$48 Million 31
ZIOPHARM Oncology Completes Private Placement Of US$5 Million 33
ZIOPHARM Oncology, Inc. – Key Competitors 35
Key Employees 36
Locations And Subsidiaries 37
Head Office 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
ZIOPHARM Oncology, Inc., Deals By Therapy Area, 2009 to YTD 2015 8
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
Ziopharm Expands Co-Development Agreement with Intrexon 10
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 11
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 13
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 14
Intrexon, Ziopharm Oncology Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 16
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 18
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 20
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 22
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 24
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 25
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 27
ZIOPHARM Oncology Completes Underwritten Public Offering For US$35 Million 29
ZIOPHARM Oncology Completes Public Offering For US$48 Million 31
ZIOPHARM Oncology Completes Private Placement Of US$5 Million 33
ZIOPHARM Oncology, Inc., Key Competitors 35
ZIOPHARM Oncology, Inc., Key Employees 36

List of Figures
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 6
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8

★海外企業調査レポート[ZIOPHARM Oncology, Inc. (ZIOP)(製薬・医療分野):企業M&A動向]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kuehne + Nagel International AG:企業の戦略・SWOT・財務分析
    SummaryKuehne + Nagel International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the comp …
  • Thye Ming Industrial Co., Ltd. (9927):企業の財務及び戦略的SWOT分析
    Summary Thye Ming Industrial Co., Ltd. (TMI) is a lead manufacturing company that develops, produces and markets calcium lead alloy and antimony lead alloys. The company's products include litharge, red lead, antimonial lead alloy, calcium lead alloy, and lead ingot. TMI’s products are used in stora …
  • Aquamarine Power Ltd.:企業のM&A・提携動向(エネルギー分野)
    Summary Aquamarine Power Ltd. (Aquamarine) a subsidiary of SSE plc is a marine company that develops marine energy projects. Its product Oyster is hydro-electric wave power converter designed to capture the energy in amplified surge forces and near shore waves. The company provides installation serv …
  • The Leukemia & Lymphoma Society, Inc.(製薬・医療分野):企業M&A動向
    Summary The Leukemia & Lymphoma Society, Inc. (LLS) is a healthcare organization. The organization provides funding to blood cancer research, and offers education and patient services. It provides services, such as fund raising, patient services, health education, policy advocacy and medical researc …
  • Korea East-West Power Co., Ltd.:企業のM&A・提携動向(エネルギー分野)
    Summary Korea East-West Power Co., Ltd. (EWP) is a state-owned electric utility that generates power from varied sources. It produces electricity from coal, oil, liquefied natural gas, mini hydro, and renewable sources such as solar, wind, biomass and bio gas. The company has operational interests i …
  • Hydra Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Hydra Biosciences Inc (Hydra) is a biopharmaceutical company that develops novel drugs. The company’s pipeline candidate HX-100 is developed to treat diabetic neuropathy and allergic asthma. It offers other drugs for the therapeutic areas including inflammation, pain, renal, anxiety and pulm …
  • Ametek, Inc. (AME):企業のM&A・提携動向(エネルギー分野)
    Summary Ametek, Inc. (Ametek) is a medical equipment company that manufactures engineered medical components. The company offers products such as materials and engineered components, measurement and test equipment and motion control products. Its materials and engineered components include titanium, …
  • Biofuels Power Corporation (BFLS):企業の財務及び戦略的SWOT分析
    Summary Biofuels Power Corporation (Biofuels Power) is an alternative fuel company that provides development of bio fuels. The company provides grid connected biodiesel power electric generation plants. It produces fuels through transesterification of off-spec oils and gasification of waste products …
  • Competitive Power Ventures Holdings, LLC:企業概要及び戦略的SWOT分析
    Competitive Power Ventures Holdings, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • West China Cement Limited:企業の戦略・SWOT・財務分析
    SummaryWest China Cement Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. K …
  • KBC Group NV (KBC):企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "KBC Group NV" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly follows a st …
  • Creston Moly Corp. (formerly Georgia Ventures, Inc.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Creston Moly Corp. (formerly Ge …
  • Adira Energy Ltd. (ADENF):企業のM&A・提携動向(石油・ガス分野)
    Summary Adira Energy Ltd. (Adira Energy) is an oil and gas exploration company that acquires and explores oil and gas resource properties. The company undertakes oil and gas projects in Israel. It also holds interest in three offshore petroleum projects in Gabriella, Yitzhak and Samuel. Adira Energy …
  • Micronas Semiconductor Holding AG (MASN):企業概要、財務及び戦略的SWOT分析
    Summary Micronas Semiconductor Holding AG (Micronas) is an electronic equipment manufacturer. The company develops and markets sensors and embedded controllers for automotive and industrial applications. Its products include hall switches, linear hall sensors, direct angle sensors, current transduce …
  • Lafarge Malaysia Berhad (LAFMSIA):企業財務及び戦略的SWOT分析
    Summary Lafarge Malaysia Berhad (LMB) is a construction material manufacturer that markets ready-mixed concrete, cement, and related building materials. The company was formerly known as Lafarge Malayan Cement Bhd. It offers cement products such as rumah, phoenix, walcrete, mascrete LH, mascrete pro …
  • PT Pertamina (Persero):企業のM&A・提携動向(発電分野)
    Summary PT Pertamina (Persero) (Pertamina) is a state controlled, integrated oil and gas company. It carries out upstream and downstream business activities in oil and gas industry. The upstream sector comprises of oil, gas and geothermal energy exploration and production. The downstream activities …
  • Swiber Holdings Ltd (AK3)-石油・ガス分野:企業M&A・提携分析
    Summary Swiber Holdings Limited (Swiber) is a provider of integrated offshore construction and support services to the oil and gas industry. The company offers offshore engineering, procurement, installation and construction (EPIC) and marine support services. Its offshore construction services incl …
  • PRAMAC S.p.A.の企業概要及び財務/SWOT分析
    PRAMAC S.p.A. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecas …
  • CareGroup, Inc.:企業の戦略的SWOT分析
    CareGroup, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Silvermet Inc.:企業の戦略・SWOT・財務分析
    SummarySilvermet Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆